Atropisomerism in the pharmaceutically relevant realm
M Basilaia, MH Chen, J Secka… - Accounts of Chemical …, 2022 - ACS Publications
Conspectus Atropisomerism is a conformational chirality that occurs when there is hindered
rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in …
rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in …
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology
RI Haddad, L Bischoff, D Ball, V Bernet… - Journal of the National …, 2022 - jnccn.org
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …
[HTML][HTML] Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
Neuronal regulation of type 2 innate lymphoid cells via neuromedin U
V Cardoso, J Chesné, H Ribeiro, B García-Cassani… - Nature, 2017 - nature.com
Group 2 innate lymphoid cells (ILC2s) regulate inflammation, tissue repair and metabolic
homeostasis, and are activated by host-derived cytokines and alarmins. Discrete subsets of …
homeostasis, and are activated by host-derived cytokines and alarmins. Discrete subsets of …
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
Antiangiogenic therapy in oncology: current status and future directions
Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been
validated as a target in several tumour types through randomised trials, incorporating …
validated as a target in several tumour types through randomised trials, incorporating …
Neuro-mesenchymal units control ILC2 and obesity via a brain–adipose circuit
F Cardoso, RGJ Klein Wolterink, C Godinho-Silva… - Nature, 2021 - nature.com
Signals from sympathetic neurons and immune cells regulate adipocytes and thereby
contribute to fat tissue biology. Interactions between the nervous and immune systems have …
contribute to fat tissue biology. Interactions between the nervous and immune systems have …
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due
to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK …
to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK …